Shanghai Pharmaceuticals Holding Co. Ltd. Class A

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class A carries a market capitalization of 57.11B, placing it among publicly traded companies globally. Its enterprise value stands at 78.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Pharmaceuticals Holding Co. Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class A has 3.71B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class A maintains a current ratio of 1.34, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class A recorded 1.82B in income tax expense.

As of the close on October 22, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class A's stock has declined approximately 11.86% over the past 52 weeks. The 50-day moving average sits at 16.40, while the 200-day moving average is 16.78.

As of June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class A holds 45.99B in cash and equivalents against 52.98B in total debt, resulting in a net debt position of 13.23B. Total book value stands at 78.35B, with working capital of 47.96B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Pharmaceuticals Holding Co. Ltd. Class A paid dividends of 0.38 per share.

Shanghai Pharmaceuticals Holding Co. Ltd. Class A's most recent stock split took place on August 16, 2007 with a 5:6 split ratio.